PLI.TO : Summary for PROMETIC LIFE SCIENCES INC. - Yahoo Finance

Canadian Markets close in 48 mins.

ProMetic Life Sciences Inc. (PLI.TO)


Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
2.27+0.10 (+4.61%)
As of 2:57PM EST. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.17
Open2.21
Bid2.26 x
Ask2.27 x
Day's Range2.20 - 2.29
52 Week Range1.47 - 3.49
Volume2,161,000
Avg. Volume2,984,868
Market Cap1.41B
Beta2.37
PE Ratio (TTM)-18.02
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire8 hours ago

    European Commission grants orphan drug designation to ProMetic's PBI-4050 drug for the treatment of Alström Syndrome

    LAVAL, QC, Jan. 18, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. (PLI.TO) (PFSCF), ("ProMetic" or the "Corporation") announced today that its orally active lead drug candidate, PBI-4050, has been granted an orphan drug designation status for the treatment of Alström Syndrome ("AS") by the European Commission. The European Medicines Agency ("EMA") determined that the intention to treat AS with PBI-4050 was justified based on the preliminary clinical data generated in AS patients showing an improvement in liver fibrosis.  ProMetic is currently investigating the effects of PBI-4050 on multiple organs in AS patients in an ongoing open label Phase 2 clinical study in the UK. "The positive results in patients with AS nicely complement those already observed in our other trials in idiopathic pulmonary fibrosis and in metabolic syndrome and type 2 diabetes" commented Dr. John Moran, ProMetic's Chief Medical Officer.

  • ProMetic Life Sciences, Inc. – Value Analysis (TORONTO:PLI) : January 12, 2017
    Capital Cube6 days ago

    ProMetic Life Sciences, Inc. – Value Analysis (TORONTO:PLI) : January 12, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives ProMetic Life Sciences, Inc. a score of 41. Our analysis is based on comparing ProMetic Life Sciences, Inc. with the following peers – Microbix Biosystems Inc., Ceapro Inc., Cipher Pharmaceuticals Inc., Sirona Biochem Corp., Spectral Medical Inc, Sophiris Bio Inc., Valeant Pharmaceuticals International Inc and Cerus Corporation ... Read more (Read more...)

  • Capital Cube7 days ago

    ETFs with exposure to ProMetic Life Sciences, Inc. : January 11, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to ProMetic Life Sciences, Inc. Here are 5 ETFs with the largest exposure to PLI-CA. Comparing the performance and risk of ProMetic Life Sciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)